These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 5312787)

  • 41. Biliary chloramphenicol excretion. 3. Following intramuscular administration of suspensions of different provenance.
    Havelka J
    Rev Czech Med; 1973; 19(1):39-46. PubMed ID: 4693323
    [No Abstract]   [Full Text] [Related]  

  • 42. Identification of chloramphenicol metabolites and some factors affecting metabolic disposition.
    Glazko AJ
    Antimicrob Agents Chemother (Bethesda); 1966; 6():655-65. PubMed ID: 5985304
    [No Abstract]   [Full Text] [Related]  

  • 43. Excretion of chloramphenicol in human milk.
    Havelka J; Hejzlar M; Popov V; Viktorinová D; Procházka J
    Chemotherapia (Basel); 1968; 13(4):204-11. PubMed ID: 5750653
    [No Abstract]   [Full Text] [Related]  

  • 44. [Adverse effects of chloramphenicol in newborn infants].
    Havelka J; Franková A
    Cesk Pediatr; 1972 Jan; 27(1):31-3. PubMed ID: 5010584
    [No Abstract]   [Full Text] [Related]  

  • 45. [Fat metabolism of the healthy infant].
    Wolf H; Löhr H
    Ergeb Inn Med Kinderheilkd; 1967; 25():25-74. PubMed ID: 4891055
    [No Abstract]   [Full Text] [Related]  

  • 46. [Evaluation of therapeutic results in acute infections in children using Chloromycetin Sol].
    Nakazawa S; Oka S; Oishi H; Arai K; Yamagishi M
    J Antibiot B; 1967 Apr; 20(2):147-51. PubMed ID: 5299157
    [No Abstract]   [Full Text] [Related]  

  • 47. An evaluation of the biological availability of chloramphenicol.
    Koeleman HA; Van Oudtshoorn MC
    S Afr Med J; 1973 Jan; 47(3):94-9. PubMed ID: 4631423
    [No Abstract]   [Full Text] [Related]  

  • 48. Excretion of chloramphenicol and its metabolites by the chronically diseased kidney (with respect to the theory of adaptive nephrons).
    Schück O; Prát V; Grafnetterová J; Kotanová E; Reitschlägerová V; David I
    Int J Clin Pharmacol; 1974 Jul; 10(1):33-43. PubMed ID: 4851956
    [No Abstract]   [Full Text] [Related]  

  • 49. Absorption of chloramphenicol by various routes of administration.
    Shah PN; D'Souza J; Dattani KK
    Indian J Med Res; 1977 Apr; 65(4):549-53. PubMed ID: 908607
    [No Abstract]   [Full Text] [Related]  

  • 50. [Maternal breast feeding].
    Huraux-Rendu C; Pesnel G
    Soins; 1982 Apr; (11):3-16. PubMed ID: 6919241
    [No Abstract]   [Full Text] [Related]  

  • 51. [Defense mechanisms of the infant and maternal milk].
    Dluholucký S
    Cesk Pediatr; 1978 Jul; 33(7):410-3. PubMed ID: 699149
    [No Abstract]   [Full Text] [Related]  

  • 52. [Probability of a blood damage by chloramphenicol].
    Kopp H; Janz B; Knaust K
    Ther Ggw; 1969 May; 108(5):764 passim. PubMed ID: 5376948
    [No Abstract]   [Full Text] [Related]  

  • 53. An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects.
    Glazko AJ; Kinkel AW; Alegnani WC; Holmes EL
    Clin Pharmacol Ther; 1968; 9(4):472-83. PubMed ID: 5655479
    [No Abstract]   [Full Text] [Related]  

  • 54. Chloramphenicol metabolism in the phenobarbital-induced rat. Comparison with thiamphenicol.
    Bella DD; Marca G; Ferrari V; Bonanomi L
    Biochem Pharmacol; 1968 Dec; 17(12):2381-90. PubMed ID: 5720346
    [No Abstract]   [Full Text] [Related]  

  • 55. [Pharmacokinetics of drugs from the breast-feeding mother passing into the body of the infant, using theophylline as an example].
    Reinhardt D; Richter O; Brandenburg G
    Monatsschr Kinderheilkd; 1983 Feb; 131(2):66-70. PubMed ID: 6843559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Bioavailability of levomycetin preparations for oral use].
    Batuashvili TA; Zak AF
    Antibiotiki; 1983 Oct; 28(10):751-4. PubMed ID: 6651263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of chloramphenicol acid succinate therapy of induced typhoid fever and rocky mountain spotted fever.
    DuPont HL; Hornick RB; Weiss CF; Snyder MJ; Woodward TE
    N Engl J Med; 1970 Jan; 282(2):53-7. PubMed ID: 4982445
    [No Abstract]   [Full Text] [Related]  

  • 58. [The influence of pharmaceutical and physico-chemical factors of drugs on the result of clinical trials: chloramphenicol palmitate].
    van Oudtshoorn MC; Potgieter FJ; Koeleman HA; Pantonowitz LD
    S Afr Med J; 1969 Nov; 43(45):1375-6. PubMed ID: 4902056
    [No Abstract]   [Full Text] [Related]  

  • 59. [Unfavorable effects on the fetus and newborn of maternal drug therapy in the puerperal state. II. The puerperium].
    Massobrio M; Colla G
    Minerva Ginecol; 1967 Nov; 19(21):1048-56. PubMed ID: 5629160
    [No Abstract]   [Full Text] [Related]  

  • 60. The pharmacokinetics of chloramphenicol in the neonate and young infant.
    Mulhall A; de Louvois J; Hurley R
    J Antimicrob Chemother; 1983 Dec; 12(6):629-39. PubMed ID: 6662841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.